The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Investigators Assess Infection Risk with RA Biologics

Investigators Assess Infection Risk with RA Biologics

August 29, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of Rheumatology.

You Might Also Like
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Denosumab Does Not Increase Risk of Infection in RA Patients
  • RA Patients on DMARDs Have Higher Risk of Infection
Also By This Author
  • Researchers Probe the Role of Fat Cells in Inflammation

The precise infection risk posed by new biologic therapies can be an elusive data point, in part because most trials aren’t powered to detect them, said Olivier Lortholary, MD, PhD, professor and chair of infectious and tropical diseases at Hôpital Necker-Enfants malades in Paris. Mining health registries is often the best way to find answers, he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s not so easy to decipher the relationship between biologics and infections during RA,” Dr. Lortholary said. “I want to emphasize the quality and the necessity of registries that are heterogeneous, but correspond to real-life patients with a bigger sample size for detecting rare events.”

Confounders in studies of RA patients include an increased infection risk even when untreated, co-morbidities that may pose an infection risk and being prescribed multiple immunosuppressive drugs, which make it even more tricky to determine the risk of an individual therapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In recent years, one of the most comprehensive looks at biologic therapy and infection risk in RA was a meta-analysis covering 70 trials. Investigators found biologic agents are linked to a “small, but significant risk [of infection],” having resulted in 1.7 excess infections per 1,000 patients treated.1

When pivotal trials are conducted, Dr. Lortholary said, infection risk can go undetected. Example: It wasn’t until infliximab had won approval and been in real-world use that the increased risk of tuberculosis was discovered.

The risk of infection associate with a biologic agent depends on a range of factors, including the drug’s presumed effect on the immune response, the drug structure, evidence found during experimental infections, and primary immunodeficiencies and the epidemiology of pathogens, Dr. Lortholary said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For tuberculosis, in particular, the risk is three to four times higher when a patient is on an anti-TNF drug, he said. So it’s important to start a tuberculosis-screening program, treat for latent tuberculosis and not restart anti-TNF drugs until clinical improvement, he said.

A recently published prospective observational cohort study from the British Society for Rheumatology Biologics Registry found the rate of tuberculosis among RA patients on biologic therapy plummeted from 783 cases per 100,000 patient-years in 2002 to 38 cases per 100,000 patient-years in 2015.2 Non-tuberculosis opportunistic infections were found at a rate of 134 per 100,000 patient-years. Researchers saw no differences in the overall rate of opportunistic infection between biologic drug classes, which included rituximab, anti-TNF and anti-IL6 therapies.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biologic drugs, EULAR, Infection, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Denosumab Does Not Increase Risk of Infection in RA Patients
  • RA Patients on DMARDs Have Higher Risk of Infection
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)